Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

2.3K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
2.3K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

2.5K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
2.5K
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

895
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
895
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

393
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
393
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

944
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
944
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

373
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
373

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Role of Polyunsaturated Fatty Acids (PUFAs) in the Primary Prevention of Allergic Diseases in Children: A Position Paper of the SIAIP Primary and Secondary Prevention of Allergic Diseases and Nutraceuticals Committees.

Nutrients·2026
Same author

Micronutrient status and growth outcomes in children with cow's milk allergy: beyond elimination diets.

Frontiers in nutrition·2026
Same author

Evidence-Based Clinical Recommendations for the Appropriate Use of Diagnostic Tests in Pediatric Allergology: Focus on Asthma, Rhinoconjunctivitis, and Keratoconjunctivitis Vernal.

Journal of clinical medicine·2026
Same author

Emerging Paediatric Uses of Dupilumab Beyond Approvals.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology·2026
Same author

Hypertransaminasemia Is a Marker of Severity in Children Hospitalized for Influenza.

Influenza and other respiratory viruses·2026
Same author

Biological drugs for the treatment of children with atopic dermatitis.

Expert opinion on biological therapy·2026

Related Experiment Video

Updated: Apr 20, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

11.2K

Omalizumab in children.

Amelia Licari1, Alessia Marseglia, Silvia Caimmi

  • 1Department of Pediatrics, University of Pavia, Fondazione IRCCS San Matteo, Pavia, Italy.

Paediatric Drugs
|November 19, 2014
PubMed
Summary

Omalizumab effectively treats pediatric allergic asthma and chronic spontaneous urticaria by reducing immunoglobulin E (IgE). Its potential in other IgE-mediated and non-IgE-mediated diseases is under investigation.

More Related Videos

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

16.5K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.7K

Related Experiment Videos

Last Updated: Apr 20, 2026

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels
05:31

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

11.2K
Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

16.5K
An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay
09:14

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

Published on: January 26, 2019

11.7K

Area of Science:

  • Immunology
  • Pediatric Allergy
  • Pharmacology

Background:

  • Omalizumab is a monoclonal antibody targeting immunoglobulin E (IgE).
  • Current pediatric use is limited to moderate-to-severe allergic asthma and chronic spontaneous urticaria (CSU).
  • Off-label use requires careful consideration.

Purpose of the Study:

  • To review approved pediatric indications for omalizumab.
  • To explore potential applications in other IgE-mediated allergic diseases.
  • To assess emerging uses in non-IgE-mediated conditions in children.

Main Methods:

  • Review of clinical trial data in pediatric populations.
  • Analysis of published literature on omalizumab's efficacy and safety.
  • Evaluation of IgE-mediated and non-IgE-mediated disease applications.

Main Results:

  • Omalizumab is effective and well-tolerated for approved pediatric indications.
  • Evidence suggests potential benefits in allergic rhinitis, food allergy, and anaphylaxis.
  • Exploration of omalizumab in non-IgE-mediated diseases is ongoing.

Conclusions:

  • Omalizumab offers a valuable therapeutic option for specific pediatric allergic conditions.
  • Further research is warranted to establish efficacy and safety in expanded indications.
  • The review highlights omalizumab's evolving role in pediatric immunology.